Neurocrine Biosciences
Yahoo Finance • 5 days ago
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference cal... Full story
Yahoo Finance • 17 days ago
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the high growth NASDAQ stocks to buy now. On June 15, Neurocrine Biosciences presented two-year Phase 3 data at ENDO 2026 showing that CRENESSITY (crinecerfont) improves growth outcomes i... Full story
Yahoo Finance • 20 days ago
Best Value Stocks to Buy for June 24th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 24: Navigator Holdings Ltd. NVGS: This global operator of a fleet of liquefied gas carriers carries a Zacks Rank #1, and has witnes... Full story
Yahoo Finance • 25 days ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story
Yahoo Finance • 29 days ago
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
Is NBIX a good stock to buy? We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on NBIX. Neurocrine Biosciences, Inc.'s share was trading at $159.7... Full story
Yahoo Finance • last month
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 15 Most Promising Stocks to Buy Right Now. On May 29, 2026, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $183 from $180 and maintaine... Full story
Yahoo Finance • 2 months ago
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:(PRNewsfoto/Neurocrine Biosciences, Inc.) William Blair 46th An... Full story
Yahoo Finance • 2 months ago
A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why INGREZZA data matters for Neurocrine Biosciences stock Neurocrine Biosciences (NBIX) has drawn fresh attention af... Full story
Yahoo Finance • 2 months ago
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced the presentation of new data from a clinician survey highlighting the functional impact of INGREZZA capsules on patients with mild tardive dyskinesia (TD) at American Psychiatric As... Full story
Yahoo Finance • 2 months ago
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia i... Full story
Yahoo Finance • 2 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Acke... Full story
Yahoo Finance • 2 months ago
Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalys... Full story
Yahoo Finance • 3 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)
BALA CYNWYD, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story
Yahoo Finance • 3 months ago
Catalyst Watch: Earnings heat up, Fedspeak flurry, and eyes on space
[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story
Yahoo Finance • 3 months ago
Neurocrine to acquire Soleno in $2.9bn transaction
Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value. The transaction will expand Neurocrine’s portfolio in endocri... Full story
Yahoo Finance • 3 months ago
Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 Stocks With Unexpected Gains. Soleno Therapeutics soared by 32.31 percent on Monday to close at $52.25 apiece, as investors gobbled up shares following news that it is set to be acqu... Full story
Yahoo Finance • 3 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)
BALA CYNWYD, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story
Yahoo Finance • 3 months ago
Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share
Soleno Therapeutics logo Key Points Neurocrine will acquire Soleno in an all-cash tender offer at $53 per share, valuing the deal at about $2.9 billion, funded with cash on hand and not subject to a financing condition. VYKAT XR, approve... Full story
Yahoo Finance • 3 months ago
Top Midday Stories: Iran Reportedly Rejects Proposed Ceasefire; Soleno Shares Rise After $2.9 Billion Neurocrine Deal
All three major US stock indexes were edging higher in late-morning trading Monday as investors weig PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 3 months ago
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster
Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story